SINGAPORE (Jan 31): A biotech company with offices in Singapore and San Francisco, Engine Biosciences, says it has secured US$10 million ($13.1 million) in seed funding from both American and Asian investors.

The heavily-oversubscribed seed round makes it the largest seed financing recorded in Southeast Asia, and one of the largest in Asia in the tech and biotech industries, according to Engine.

It was co-led by Silicon Valley’s Danhua Capital (DHVC) and 6 Dimensions Capital, a healthcare investment group formed through the merger of Frontline Bioventures and Wuxi Healthcare Ventures.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook